[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":330},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,41,63,85,106,129,153,176,199,221,243,263,284,306],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100631963","phase-2-the-purpose-of-this-study-is-to-evaluate-the-efficacy-and-safety-of-627-in-the-treatment-of-uc-100631963",false,"NCT07507513","The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Immunogenicity of SSGJ-627 in Subjects With Moderate to Severe Active Ulcerative Colitis (UC)","Inclusion Criteria:\n\n1. Able to understand and comply with the requirements of the study protocol, and sign the written informed consent form (ICF).\n2. Male or female subjects aged 18-75 years old when signing the ICF.\n3. Subjects must have been diagnosed with UC for at least 3 months prior to randomization.\n4. Moderate to Severe Active Ulcerative Colitis (UC).\n5. Inadequate or lost response, intolerance to one or more therapies, or corticosteroid dependence.\n6. Female subjects of childbearing potential and male subjects (and their female partners) must use highly effective contraception from the screening period through at least 6 months after the last dose. The subjects must have no plans for pregnancy, sperm donation, or oocyte donation during the same period (from screening through at least 6 months post-last dose).\n\nExclusion Criteria:\n\n1. History of severe opportunistic infection within 2 months prior to screening or randomization that remains not adequately controlled.\n2. Receiving protocol-prohibited treatments prior to screening or randomization.\n3. Presence of any laboratory test abnormalities during screening and\u002For determination by the investigator that enrollment in the study may pose uncontrollable safety risks to the subject.\n4. Positive hepatitis B test result, positive hepatitis C virus antibody (HCV Ab), positive human immunodeficiency virus antibody (HIV Ab), or positive serum Treponema pallidum antibody (TP Ab) during screening, as specified in the protocol.\n5. History of clinically significant cardiovascular and cerebrovascular diseases within 6 months prior to screening.\n6. History of any malignancy within 5 years prior to screening or currently active malignancy.\n7. Allergy to the investigational medicinal product, any of its components, or excipients.\n8. History of alcohol or substance abuse within 6 months prior to screening.\n9. Undergone major surgery within 6 months prior to screening or planned major surgery during the study period.\n10. Blood donation or significant blood loss within 4 weeks prior to screening.\n11. Participation in any drug clinical trial within 3 months prior to screening or within 5 half-lives of the investigational drug (whichever is longer).\n12. Vaccination with live\u002Fattenuated live vaccines within 4 weeks prior to screening or planned vaccination during the study period.\n13. Pregnant or lactating female subjects.\n14. Other conditions deemed unsuitable for trial participation by the investigator.","ALL","18 Years","75 Years",{"count":20,"type":21},288,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study will evaluate the efficacy and safety of 627 in patients with UC.",[27],"Ulcerative Colitis (UC)","NOT_YET_RECRUITING","2026-03-26",{"date":31,"type":32},"2026-04-02","ACTUAL",{"date":34,"type":21},"2026-03-31",{"date":36,"type":21},"2029-12-30",{"name":38,"class":39},"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":40},"100619800","phase-3-a-study-to-evaluate-the-efficacy-and-safty-of-608-in-patients-with-non--radiographic-axial-spondyloarthritis-nr-axspa-100619800","NCT07349329","A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)","A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of 608 in Patients With Non-radiographic Axial Spondyloarthritis (Nr-axSpA)","Inclusion Criteria:\n\n1. Female and male patients at least 18 years of age at the time of screening.\n2. Diagnosis of axial spondyloarthritis according to Ankylosing Spondylo Arthritis International Society (ASAS) axial spondyloarthritis criteria\n3. Objective signs of inflammation (magnetic resonance imaging (MRI) or abnormal C-reactive protein)\n4. Total back pain as measured by NRS ≥ 4 at baseline\n\nExclusion Criteria:\n\n1. Patients with other uncontrolled active inflammatory diseases.\n2. Clinical laboratory tests and other tests that reveal abnormalities with clinical significance\n3. Patients who have active Hepatitis B, Hepatitis C or HIV infections as determined by positive results at Screening.\n4. History of cancer.\n5. Known or suspected history of immunosuppression.\n6. Known with allergic or intolerant to mometasone furoate spray or 608\u002Fplacebo.",{"count":49,"type":21},380,[51],"PHASE3","This study will evaluate the efficacy and safety of 608 in patients with nr-axSpA.",[54],"Axial Spondyloarthritis, Non-Radiographic","2026-01-09",{"date":57,"type":32},"2026-01-16",{"date":59,"type":21},"2026-03-09",{"date":61,"type":21},"2029-02-21",{"name":38,"class":39},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":70,"targetDuration":4,"studyType":22,"phases":72,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":40},"100540927","phase-3-efficacy-and-safety-study-of-610-in-patients-with-severe-asthma-100540927","NCT06323213","Efficacy and Safety Study of 610 in Patients With Severe Asthma","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of 610 in Chinese Adult Subjects With Severe Eosinophilic Asthma","Inclusion Criteria:\n\n1. Able to give written informed consent prior to participation in the study.\n2. Male or female adults ages 18 to 75 years old when signing the informed consent.\n3. Documented diagnosis of asthma for at least one year prior to screening.\n4. History of physician-diagnosed asthma requiring treatment with ICS and at least one other control medication for at least 6 months prior to screening.\n\nExclusion Criteria:\n\n1. Presence of a known pre-existing, clinically important lung condition other than asthma.\n2. Severe asthma exacerbation within 4 weeks prior to randomization.\n3. Subjects with any eosinophilic diseases other than asthma.\n4. Known, pre-existing severe or clinically significant cardiovascular disease.\n5. known, pre-existing other concurrent clinically significant medical conditions that are uncontrolled with standard treatment.\n6. Subjects who have active Hepatitis B, Hepatitis C or HIV infections as determined by positive results at Screening.\n7. Subjects with allergy\u002Fintolerance to a monoclonal antibody.",{"count":71,"type":21},480,[51],"The primary objective of the study is to evaluate the efficacy and safety of 610 in Chinese adults with severe asthma.",[75],"Asthma","RECRUITING","2026-01-04",{"date":79,"type":32},"2026-01-07",{"date":81,"type":32},"2024-06-24",{"date":83,"type":21},"2027-09",{"name":38,"class":39},{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":40},"100613058","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-608-in-adult-subjects-with-active-ankylosing-spondylitisas-100613058","NCT07261644","A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis (AS)","Inclusion Criteria:\n\n1. Able to understand and comply with the protocol requirements, participate and sign the informed consent form (ICF) voluntarily;\n2. At least 18 years of age at the time of signing the ICF, with no gender restrictions;\n3. Meet the 1984 modified New York criteria for ankylosing spondylitis (AS);\n4. Have inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs) or have contraindications\u002Fintolerance to NSAIDs treatment;\n5. Willing to practice contraception and have no plans for pregnancy, sperm donation, or egg donation from the screening period until at least 6 months after the last dose.\n\nExclusion Criteria:\n\n1. Patients with other uncontrolled active inflammatory diseases.\n2. Clinical laboratory tests and other tests that reveal abnormalities with clinical significance\n3. Patients who have active Hepatitis B, Hepatitis C or HIV infections as determined by positive results at Screening.\n4. History of cancer.\n5. Known or suspected history of immunosuppression.",{"count":93,"type":21},500,[51],"This study will evaluate the efficacy and safety of 608 in patients with AS.",[97],"Ankylosing Spondylitis","2025-12-03",{"date":100,"type":32},"2025-12-10",{"date":102,"type":32},"2025-11-07",{"date":104,"type":21},"2027-11-18",{"name":38,"class":39},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":40},"100607185","phase-1-the-purpose-of-this-study-is-to-evaluate-the-efficacy-and-safety-of-626-in-the-treatment-of-sle-100607185","NCT07185269","The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ib\u002FII Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Anti-BDCA2 Antibody SSGJ-626 in Subjects With Systemic Lupus Erythematosus","Inclusion Criteria:\n\n* Able to understand protocol requirements and sign a written ICF.\n* Male or female subjects aged 18-70 years when signing the ICF.\n* Body weight between 40 and 90 kg.\n* Diagnosed with SLE at least 6 months before the Screening Visit by a qualified physician，confirmed according to the 2019 SLE European League Against Rheumatism\u002FAmerican College of Rheumatology (EULAR\u002FACR) classification criteria for SLE.\n* At screening, meet at least one of the following criteria:\n\n  1. Anti-nuclear antibody (ANA) titer ≥ 1:80;\n  2. Positive anti-dsDNA antibody..\n* Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) ≥6 with clinical SLEDAI score ≥4 points at Screening and Baseline Visit .\n* Currently receiving at least one of the SOC SLE medications: oral corticosteroid, antimalarial and\u002For immunosuppressive agent.\n\nExclusion Criteria:\n\n* Study participant has a mixed connective tissue disease, and\u002For overlap syndrome of systemic lupus erythematosus (SLE) with systemic sclerosis.\n* Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric SLE) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study. This includes study participants with a life-threatening condition\n* Patients who have active Hepatitis B, Hepatitis C or HIV infections as determined by positive results at Screening.\n* History of cancer.\n* Active severe lupus nephritis present within 2 months prior to baseline. Or estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m2, or protein:creatinine ratio \\>2.0 g\u002Fg.","70 Years",{"count":115,"type":21},198,[117,24],"PHASE1","This study will evaluate the effect and safety of 626 in patients with SLE",[120],"Systemic Lupus Erythematosus (SLE)","2025-11-25",{"date":123,"type":32},"2025-11-26",{"date":125,"type":32},"2025-09-24",{"date":127,"type":21},"2028-11-04",{"name":38,"class":39},{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":152},"100595993","phase-3-evaluation-of-611-in-chinese-adults-patients-with-moderate-to-severe-chronic-obstructive-pulmonary-disease-100595993","NCT07039669","Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","A Multi-Centered, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial, to Evaluate the Efficacy and Safety of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease","Inclusion Criteria:\n\n1. Able to understand and follow the protocol requirements, and give written informed consent prior to participation voluntarily in the study.\n2. Male or female adults ages 40 to 85 years old when signing the informed consent.\n3. Current or former smokers with a smoking history of ≥10 pack-years.\n4. Documented diagnosis of COPD for at least 12 months prior to enrolment\n5. Moderate-to-severe COPD.\n6. Documented history of ≥ 2 moderate or ≥ 1 severe COPD exacerbations within 12 months prior to enrolment.\n7. Background triple therapy (ICS + LABA + LAMA) for 3 months prior to randomization with a stable dose of medication for ≥ 1 month prior to randomization; Double therapy (LABA + LAMA) allowed if ICS is contraindicated.\n8. Female subjects of reproductive age (and their male partners) and male subjects (and their female partners) must use highly effective contraception throughout the study period and for at least 3 months after the last dose. The subjects had no plans to pregnancy, donate sperm or donate egg during the whole study period and for at least 3 months after the last dose.\n\nExclusion Criteria:\n\n1. Presence of a known pre-existing, clinically important lung condition other than COPD.\n2. A current diagnosis of asthma or history of asthma according to the Global Initiative for Asthma (GINA) guidelines or other accepted guidelines.\n3. Diagnosis of α-1 anti-trypsin deficiency.\n4. Presence of an active autoimmune disease.\n5. Subjects who have any malignant tumors within 5 years prior to enrollment.\n6. Known, pre-existing other concurrent clinically significant medical conditions that are uncontrolled.\n7. Diagnosed active parasitic infection, suspected or high risk of parasitic infection.\n8. Subjects who have active Hepatitis B, Hepatitis C or HIV infections as determined by positive results at Screening.\n9. Known with allergic or intolerant to any biological product.\n10. Any reason which, in the opinion of investigator, would prevent the subject from participating in the study.","40 Years","85 Years",{"count":139,"type":21},594,[51],"The objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD.",[143],"Pulmonary Disease, Chronic Obstructive (COPD)","2025-11-17",{"date":146,"type":32},"2025-11-18",{"date":148,"type":32},"2025-07-16",{"date":150,"type":21},"2028-11",{"name":38,"class":39},4,{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":160,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":175},"100596182","phase-3-evaluation-of-611-in-chinese-adolescents-with-moderate-to-severe-atopic-dermatitis-100596182","NCT07042126","Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis","A Multi-Center, Randomized, Double-Blind, Placebo-Ccontrolled Phase Ⅲ Clinical Trail， to Evaluate the Efficacy and Safety of 611 (Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adolescents (12 Years Old≤Age \u003C 18 Years Old) With Moderate to Severe Atopic Dermatitis (AD)","Inclusion Criteria:\n\n* The subjects and their legal guardians are able to understand and comply with the research procedures, agree to participate in the research, and sign the Informed Consent Form (ICF).\n* When signing the informed consent form, the age should be ≥ 12 years old and \\\u003C 18 years old, gender is not restricted, and the body weight should be ≥ 30 kg at the screening and baseline.\n* During the screening process, patients were diagnosed with atopic dermatitis (AD) according to the Hanifin - Rajka criteria, and their AD medical history was evaluated by researchers to be ≥ 6 months (the diagnostic criteria are not restricted for the medical history).\n* At the screening and baseline, the Eczema Area and Severity Index (EASI) score is ≥ 16 points.\n* At the screening and baseline, the Investigator Global Assessment (IGA) score is ≥3 points.\n* At the time of screening and baseline, the affected body surface area (BSA) by atopic dermatitis (AD) is ≥10%.\n* At baseline, the weekly average score of the Numerical Rating Scale (NRS) for pruritus was ≥ 4 points.\n* Subjects should have relevant medical records, other medical visit records, or other evidence within the previous year for researchers to evaluate. The subjects have poor efficacy of topical drug treatment, or are medically unsuitable for topical drug treatment.\n* Be willing to use a stable dose of emollient (moisturizer) on the affected areas of atopic dermatitis (AD) twice a day for at least 7 days before randomization and continue to use it throughout the study period.\n* Subjects with potential fertility (e.g., females who have experienced menarche or males who have had nocturnal emissions) must agree to avoid sexual activity or use highly effective contraceptive methods throughout the entire study period and for at least 3 months after the last dose of the medication.Subjects should have no plans for reproduction, sperm donation, or egg donation during the entire study period and for at least 3 months after the last dose of the medication.\n\nBe able to understand and complete (either independently or with the assistance of a guardian) the research - related questionnaire filling.\n\nExclusion Criteria:\n\n* Merge other skin comorbidities that may interfere with the research evaluation.\n* Combined with active parasitic infections (such as helminths) or suspected parasitic infections (subjects who have excluded active infections through clinical and\u002For laboratory examinations before randomization can be enrolled).\n* Any history of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC).\n* Randomly select patients with any malignant tumor diagnosed within the past 5 years or currently having the disease (excluding basal cell carcinoma that has been cured for ≥ 1 year, local cutaneous squamous cell carcinoma, or carcinoma in situ of the cervix).\n* The subject had a severe infection requiring intravenous antibiotics and\u002For hospitalization within 4 weeks before randomization, or had an active infection requiring oral antibiotics within 2 weeks before randomization, and the investigator evaluated that there might be uncontrollable risks for the subject to participate in this study.\n* A history of known or suspected immunosuppression, including a history of invasive opportunistic infections (such as histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis); or those who, although the infection has resolved, are considered by the investigator to be likely to have frequent recurrences.\n* Those with evidence of active tuberculosis, or those who have had active tuberculosis in the past but cannot provide sufficient evidence of treatment, or those who are judged to potentially have active tuberculosis infection based on examinations such as chest X - ray or CT, medical history, contact history, symptoms, and physical signs.\n* The researchers believe that there are any diseases that are severe or unstable and may affect the safety of the subjects during the study and\u002For prevent the subjects from completing the study, including but not limited to cardiovascular, gastrointestinal, liver, kidney, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, and mental diseases.\n* Currently receiving or having received the following treatments:\n\n  1. Within the first 2 weeks randomly selected, patients have received topical drug treatment for atopic dermatitis (AD), such as TCS, TCI, PDE inhibitors, Janus kinase (JAK) inhibitors, etc.\n  2. Within the first 4 weeks before randomization, the patients received systemic treatment with traditional Chinese medicine (TCM) of unknown nature or with therapeutic effects on AD. Or within the first 1 week before randomization, they received topical treatment with Chinese herbal medicine of unknown nature or with therapeutic effects on AD.\n  3. Received systemic glucocorticoids or other immunosuppressants\u002Fimmunomodulators (including but not limited to cyclosporine, mycophenolate mofetil, interferon γ \\[IFN-γ\\], JAK inhibitors, compound glycyrrhizin, azathioprine, mycophenolate mofetil, and methotrexate) randomly within the first 4 weeks or 5 half - lives (whichever is longer).\n  4. Received phototherapy (including but not limited to narrow - band ultraviolet B \\[NBUVB\\], ultraviolet B \\[UVB\\], ultraviolet A1 \\[UVA1\\], psoralen plus ultraviolet A \\[PUVA\\]), tanning beds, or any other light - emitting devices with therapeutic effects on atopic dermatitis (AD) within the first 4 weeks randomly.\n  5. Randomly selected patients who had received allergen-specific immunotherapy (SIT) within the previous 6 months.\n  6. Received any monoclonal antibody therapy (such as dupilumab, etc.) within the first 4 months randomly or within 5 half-lives (whichever is longer) before randomization; Received any cell - depleting agents, including but not limited to rituximab, within 6 months before randomization.\n  7. As judged by the researchers, patients had no response or poor efficacy to previous treatment with anti-IL-4 and\u002For IL-13 drugs (such as dupilumab, etc.).\n  8. Previously, 611 was used.\n  9. Treatment of atopic dermatitis (AD) with prescription emollients or emollients containing additives is initiated during the screening period.\n* Received live vaccines or live attenuated vaccines within the first 4 weeks before randomization.\n* If any of the examination indicators before screening or randomization meet the following criteria and are judged by the researcher as unsuitable for inclusion in the study:TBIL≥1.5 ULN ;ALT\u002FAST ≥2 ULN；Cr\\>1.5 ULN; blood WBC is lower than LLN, which is judged by the researcher to be clinically significant and makes the subject ineligible for the study.\n* At the screening, the test results are positive for hepatitis B, positive for hepatitis C virus antibody (HCVAb), positive for human immunodeficiency virus antibody (HIVAb), and positive for serum Treponema pallidum antibody (TPAb).\n* Used any investigational drugs within the first 8 weeks after randomization or 5 half-lives (whichever is longer);\n* Had a history of alcohol or drug abuse within 6 months before randomization;\n* Known to be allergic or intolerant to any components of the investigational drug;\n* Planned or were expected to undergo major surgical operations during the study period;\n* Pregnant women, women planning to become pregnant during the study period, or breastfeeding women;\n* According to the investigator's judgment, the subjects were not suitable to participate in the study due to other diseases or reasons.","12 Years","17 Years",{"count":163,"type":21},180,[51],"The primary objective of the study was to evaluate the efficacy of 611 in Chinese Adolescents with moderate to severe atopic dermatitis.",[167],"Dermatitis, Atopic","2025-11-16",{"date":146,"type":32},{"date":171,"type":32},"2025-08-05",{"date":173,"type":21},"2027-09-30",{"name":38,"class":39},3,{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":183,"sex":16,"minAge":17,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":22,"phases":187,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":4},"100597949","phase-1-evaluation-of-627-in-healthy-adult-subjects-100597949","NCT07065136","Evaluation of 627 in Healthy Adult Subjects","A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SSGJ-627 in Healthy Adult Subjects","Inclusion Criteria:\n\n* Able to understand protocol requirements and sign a written ICF.\n* Male or female subjects aged 18-45 years when signing the ICF.\n* Male subjects with body weight ≥ 50 kg, and female subjects with body weight ≥ 45 kg. Subjects with BMI between 18 and 28 kg\u002Fm2.\n* Subjects whose test results are normal, or abnormal without clinical significance as determined by the investigator.\n* Female subjects with childbearing potential and male subjects (and their female partners) must agree to take highly effective contraceptive measures.\n\nExclusion Criteria:\n\n* History of severe allergy, or with a history of allergy to the study treatment or related excipients.\n* History of of significant alcohol abuse.\n* History of significant drug abuse.\n* Subjects who have positive result for urine nicotine test at screening.\n* Pregnant, or nursing females.",true,"45 Years",{"count":186,"type":21},108,[117],"This is a randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose phase I clinical study to evaluate the safety, tolerability, PK and immunogenicity of SSGJ-627 in healthy adult subjects after single subcutaneous injection.",[190],"Healthy Subjects (HS)","2025-07-14",{"date":193,"type":32},"2025-07-15",{"date":195,"type":21},"2025-07-20",{"date":197,"type":21},"2026-09-18",{"name":38,"class":39},{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":183,"sex":16,"minAge":17,"maxAge":184,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":208,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":220},"100596181","phase-1-a-study-of-two-different-formulations-of-611-in-healthy-adult-subjects-in-china-100596181","NCT07042113","A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China","A Randomized, Open-label, Parallel-enrollment Pharmacokinetic Comparison Study of Two Formulations of Recombinant Anti-IL-4Rα Humanized Monoclonal Antibody Injection (611) Injected Subcutaneously in Healthy Adult Subjects in China","611","Inclusion Criteria:\n\n1. Willingness to provide written informed consent for the study.\n2. Male or female subjects, age 18-45 years older.\n3. Within body mass index (BMI) range 19.0 to 26.0 kilograms per square meter (kg\u002Fm²).\n4. The results of vital signs, physical examination, laboratory tests, electrocardiogram, chest X-ray and other examinations during the screening period are normal or judged to be abnormal by the investigator and have no clinical significance.\n5. Males and females of non-childbearing potential.\n\nExclusion Criteria:\n\n1. History of severe allergies or allergies to 611 and any of its components;\n2. Previous or current disease that may affect the safety of the subject's participation in the trial or the in vivo process of the trial drug;\n3. Any history of VKC and AKC;\n4. History of drug abuse within 2 years prior to screening;\n5. Alcoholism within 3 months prior to screening;\n6. Those who smoke more than 5 cigarettes per day within 3 months before screening or cannot give up smoking during the period from signing the informed consent of the subject to leaving the group;\n7. Those who have consumed more than 1L of strong tea, coffee and\u002For caffeinated beverages per day within 3 months before screening, and who have ingested chocolate or any food or drink containing caffeine, theophylline, theobromine or alcohol within 48 hours before the study administration;\n8. Have active tuberculosis;\n9. Presence of active infection requiring systemic treatment prior to screening or dosing;\n10. Those who have used any prescription drugs, over-the-counter drugs, vitamin products or Chinese herbal medicines within 4 weeks or 5 half lives (whichever is longer) before dosing, or those who may need to receive other drugs during the trial;\n11. Participated in the clinical trial of any drug or device within 3 months or 5 half-lives before dosing;\n12. Receipt of any marketed or investigational biologic within 3 months or 5 half lives prior to dosing;\n13. Live vaccine or live attenuated vaccine within 2 months prior to dosing or planned administration during the study;\n14. Previous use of any IL-4Rα target drugs;\n15. Pregnant or lactating females;",{"count":163,"type":21},[117],"The main purpose of this study is to compare two different formulations (mixtures) of 611 in healthy participants. This study will compare how much of each formulation gets into the blood stream.",[211],"Atopic Dermatitis","2025-06-19",{"date":214,"type":32},"2025-06-27",{"date":216,"type":21},"2025-07",{"date":218,"type":21},"2026-01",{"name":38,"class":39},2,{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":22,"phases":228,"briefSummary":229,"conditions":230,"keywords":232,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":242},"100533196","phase-2-a-study-to-evaluate-608-in-patients-with-non--radiographic-axial-spondyloarthritis-nr-axspa-100533196","NCT06222671","A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)","A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of 608 in Patients With Non-radiographic Axial Spondyloarthritis (Nr-axSpA)",{"count":163,"type":21},[24],"This study will evaluate the effect and safety of 608 in patients with nr-axSpA.",[231],"Axial Spondyloarthritis",[233],"non-radiographic axial spondyloarthritis","2025-03-06",{"date":236,"type":32},"2025-03-11",{"date":238,"type":32},"2024-03-22",{"date":240,"type":21},"2025-11-30",{"name":38,"class":39},6,{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":183,"sex":16,"minAge":17,"maxAge":184,"enrollmentInfo":250,"targetDuration":4,"studyType":22,"phases":252,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":40},"100567925","phase-1-evaluation-of-626-in-healthy-adult-subjects-100567925","NCT06674525","Evaluation of 626 in Healthy Adult Subjects","A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SSGJ-626 in Healthy Adult Subjects","Inclusion Criteria:\n\n* Able to understand protocol requirements and sign a written ICF.\n* Male or female subjects aged 18-45 years when signing the ICF.\n* Male subjects with body weight ≥ 50 kg, and female subjects with body weight ≥ 45 kg. Subjects with BMI between 18 and 28 kg\u002Fm2.\n* Subjects whose test results are normal, or abnormal without clinical significance as determined by the investigator.\n* Female subjects with childbearing potential and male subjects (and their female partners) must agree to take highly effective contraceptive measures.\n\nExclusion Criteria:\n\n* History of severe allergy, or with a history of allergy to the study treatment or related excipients.\n* With any clinically significant diseases prior to the screening visit.\n* Subjects with positive test results for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibody, anti-human immunodeficiency virus (HIV) antibody.\n* History of of significant alcohol abuse.\n* History of significant drug abuse.\n* Subjects who have positive result for urine nicotine test at screening.\n* Pregnant, or nursing females.",{"count":251,"type":21},50,[117],"This is a randomized, double-blind, placebo-controlled, single ascending dose phase I clinical study to evaluate the safety, tolerability, PK and immunogenicity of SSGJ-626 in healthy adult subjects after single subcutaneous injection.",[190],"2024-12-05",{"date":257,"type":32},"2024-12-10",{"date":259,"type":32},"2024-12-02",{"date":261,"type":21},"2025-10",{"name":38,"class":39},{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":270,"targetDuration":4,"studyType":22,"phases":272,"briefSummary":273,"conditions":274,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":40},"100556263","phase-2-a-study-to-evaluate-ssgj-707-in-advanced-gynecologic-cancer-patients-100556263","NCT06522828","A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients","A Phase 2 Study to Evaluate the Safety and Efficacy of SSGJ-707 in Advanced Gynecologic Cancer Patients","Inclusion Criteria:\n\n1. Age:18-75 years old\n2. Advanced endometrial cancer and platinum-resistant ovarian cancer\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n4. Expected survival \\>=12 weeks.\n5. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Known uncontrolled or symptomatic central nervous system metastatic disease.\n2. Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \\>1 (National Cancer Institute Common terminology Criteria \\[NCI CTCAE\\] v.5.0).\n3. Inadequate organ or bone marrow function.\n4. Pregnant or breast-feeding woman.\n5. Known allergies, hypersensitivity, or intolerance to SSGJ-707 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.",{"count":271,"type":21},80,[24],"This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced\u002Frecurrent endometrial cancer and platinum-resistant ovarian cancer. The objective is to evaluate the safety, tolerability and antitumor activity of SSGJ-707 in the treatment of advanced\u002Frecurrent endometrial cancer and platinum-resistant ovarian cancer.",[275],"Advanced\u002Frecurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer","2024-10-17",{"date":278,"type":32},"2024-10-21",{"date":280,"type":32},"2024-10-10",{"date":282,"type":21},"2026-08",{"name":38,"class":39},{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":291,"targetDuration":4,"studyType":22,"phases":292,"briefSummary":293,"conditions":294,"keywords":296,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":40},"100546118","phase-1-a-study-to-evaluate-the-safety-tolerability-and-preliminary-efficacy-of-ssgj-705-monotherapy-in-patients-with-advanced-malignant-tumors-100546118","NCT06390774","A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors","A Phase I Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors","Inclusion Criteria:\n\n1. Males and\u002For females over age 18\n2. Histologically and\u002For cytologically documented local advanced or recurrent or metastatic malignancies\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n4. Expected survival \\>3 months.\n5. Signed informed consent form.\n6. Must have adequate organ function.\n\nExclusion Criteria:\n\n1. Any remaining AEs \\> grade 1 from prior anti-tumor treatment as per CTCAE v5. 0, with exception of hair loss, fatigue, and grade 2 peripheral neurotoxicity.\n2. Pregnant or nursing women or women\u002Fmen who are ready to give birth\n3. Symptomatic central nervous system metastasis.\n4. Allergy to other antibody drugs or any excipients in the study drugs.\n5. Severe dyspnea at rest due to complications of advanced malignant tumors, or needing supplemental oxygen therapy.\n6. Participated in any clinical study of medical devices or drugs within 1 month prior to screening (excluding non-intervention clinical studies or follow-up period of intervention clinical studies) .\n\nThe above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.",{"count":163,"type":21},[117],"This study was an open-label phase I study to evaluate the safety, tolerability, PK profile and potential efficacy of SSGJ-705 as a single agent in patients with advanced malignancies.",[295],"Locally Advanced, Recurrent or Metastatic Malignancies",[297],"advanced malignancies","2024-10-16",{"date":300,"type":32},"2024-10-18",{"date":302,"type":32},"2024-05-30",{"date":304,"type":21},"2027-02",{"name":38,"class":39},{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":313,"targetDuration":4,"studyType":22,"phases":315,"briefSummary":316,"conditions":317,"keywords":319,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":40},"100554028","phase-2-a-phase-2-study-of-ssgj-707-in-metastatic-colorectal-cancer-patients-100554028","NCT06493760","A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients","A Phase 2 Study to Evaluate the Safety and Efficacy of SSGJ-707 As First-Line Treatment in Metastatic Colorectal Cancer Patients","Inclusion Criteria:\n\n1. Males and\u002For females over age 18\n2. Histologically and\u002For cytologically documented metastatic colorectal cancer confirmed .\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n4. Expected survival \\>=12 weeks.\n5. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Known uncontrolled or symptomatic central nervous system metastatic disease.\n2. Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \\>1 (National Cancer Institute Common terminology Criteria \\[NCI CTCAE\\] v.5.0).\n3. Inadequate organ or bone marrow function.\n4. Pregnant or breast-feeding woman.\n5. Known allergies, hypersensitivity, or intolerance to SSGJ-707 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.",{"count":314,"type":21},130,[24],"This study includes two parts:Part 1: SSGJ-707 (different dosing regimens) in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.Part 2: SSGJ-707 in combination with chemotherapy versus bevacizumab in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.",[318],"Metastatic Colorectal Cancer",[320,321],"SSGJ-707","colorectal cancer","2024-09-04",{"date":324,"type":32},"2024-09-19",{"date":326,"type":32},"2024-09-03",{"date":328,"type":21},"2027-06",{"name":38,"class":39},""]